Tuberculosis Basic Research

NIAID supports basic research on Mycobacterium tuberculosis (Mtb), the causative agent of TB, and seeks to understand how the bacterium causes disease in humans. The Institute is accelerating efforts to identify new candidate drugs, vaccines and biomarkers and technologies with diagnostic potential to improve TB diagnosis, treatment, and prevention strategies. NIAID also supports research to map the diversity of genetic drug resistant Mtb and assess what factors influence the occurrence, distribution, and transmission of drug-sensitive and drug-resistant strains of Mtb.

Scientific Advances

World TB Day 2023 – ‘Yes! We Can End TB!’

March 24, 2023

Included in the World TB Day 2023 news release, information about how, NIAID’s Immune Mechanisms of Protection Against Mtb (IMPAc-TB) supports comprehensive research on the interaction between the immune system and Mtb to inform future TB vaccine design and development, and NIAID’s Tuberculosis Research Units (TBRUs), a collaborative network, supports research on other aspects of the interactions between Mtb and the host’s body. 

Content last reviewed on